High MYC and/or BCL2 protein expression, as assessed by immunohistochemistry, has also been shown to have an adverse prognostic impact in systemic DLBCL, independent of MYC rearrangement and COO subtype [10]–[12]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.